Back to search

Peptide record

TPDB04930

Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard
26 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB04930
Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb APD_complete APD_hemolytic Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 26-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
RFRLPFRRPPIRIHPPPFYPPFRRFL
Physicochemical Analysis
C166H247N49O28
ANDCEQGKMSTWV
P
3377.10
12.80
8
0
10
+7
1.90
-0.700
60.00
Mammalian: 1 hour Yeast: 2 min E.coli: 2 min
1490
44.12
1
Residue Composition
number
0
A
7
R
0
N
0
D
0
C
0
E
0
Q
0
G
1
H
2
I
2
L
0
K
0
M
5
F
8
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 0 R: 7 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 2 L: 2 K: 0 M: 0 F: 5 P: 8 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
26
C166H247N49O28
3377.10
12.80
+7
1.90
-0.700
Evidence Records 12 records
Evidence 1 Activity

Activity

Hemolysis
[Swiss_Prot Entry P85170]Low hemolytic activity against human red blood cells

Target

human red blood cells

Source & Reference

Hemolytik APD_complete APD_hemolytic PD_Hemolysis
DRAMP4
Submitted (MAY-2007) to UniProtKB.

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 2 Activity

Activity

50% Cytotoxicity
Toxicity
36.2±6.9 µM
Cytotoxic
50% Cytotoxicity | 36.2±6.9 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Caprine Bactenecins as Promising Tools for Developing New Antimicrobial and Antitumor Drugs. | Front Cell Infect Microbiol | 2020
Evidence 3 Activity

Activity

<5% Hemolysis
Toxicity
64 µM
Hemolytic Cytotoxic
<5% Hemolysis | 64 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Caprine Bactenecins as Promising Tools for Developing New Antimicrobial and Antitumor Drugs. | Front Cell Infect Microbiol | 2020
Evidence 4 Activity

Activity

IC50
Toxicity
>25 µM
Cytotoxic
IC50 | >25 | µM | target cell: Human fibroblasts MRC-5

Target

Human fibroblasts MRC-5

Source & Reference

NA
DBAASP
ChBac3.4: a novel proline-rich antimicrobial peptide from goat leukocytes | Int J Pept Res Ther | 2009
Evidence 5 Activity

Activity

IC50
Toxicity
>25 µM
Cytotoxic
IC50 | >25 | µM | target cell: Human skin fibroblasts

Target

Human skin fibroblasts

Source & Reference

NA
DBAASP
ChBac3.4: a novel proline-rich antimicrobial peptide from goat leukocytes | Int J Pept Res Ther | 2009
Evidence 6 Activity

Activity

6% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
6% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
ChBac3.4: a novel proline-rich antimicrobial peptide from goat leukocytes | Int J Pept Res Ther | 2009
Evidence 7 Activity

Activity

MEC
Toxicity
20 µM
Cytotoxic
MEC | 20 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance? | Front Cell Infect Microbiol | 2019
Evidence 8 Activity

Activity

MEC
Toxicity
>20 µM
Cytotoxic
MEC | >20 | µM | target cell: Human neutrophils

Target

Human neutrophils

Source & Reference

NA
DBAASP
Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance? | Front Cell Infect Microbiol | 2019
Evidence 9 Activity

Activity

MEC
Toxicity
>20 µM
Cytotoxic
MEC | >20 | µM | target cell: Murine peritoneal macrophages

Target

Murine peritoneal macrophages

Source & Reference

NA
DBAASP
Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance? | Front Cell Infect Microbiol | 2019
Evidence 10 Activity

Activity

50% Cytotoxicity
Toxicity
18.6±0.8 µM
Cytotoxic
50% Cytotoxicity | 18.6±0.8 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Caprine Bactenecins as Promising Tools for Developing New Antimicrobial and Antitumor Drugs. | Front Cell Infect Microbiol | 2020
Evidence 11 Activity

Activity

Toxicity
Hemolytic
Hemolytic_activity: [Swiss_Prot Entry P85170]Low hemolytic activity against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Submitted (MAY-2007) to UniProtKB.
Evidence 12 Hemolysis

Activity

[Swiss_Prot Entry P85170]Low hemolytic activity against human red blood cells
Hemolysis

Target

human red blood cells

Source & Reference

APD_complete APD_hemolytic PD_Hemolysis
Submitted (MAY-2007) to UniProtKB.
DRAMP4
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.